Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes

Yuan-Yun Tseng, Chen Hsing Su, Shung-Tai Yang, Yin Chen Huang, Wei-Hwa Lee, Yi Chuan Wang, Shou Cheng Liu, Shih Jung Liu

研究成果: 雜誌貢獻文章

5 引文 (Scopus)

摘要

Glioblastoma multiforme (GBM), the most prevalent and malignant form of a primary brain tumour, is resistant to chemotherapy. In this study, we concurrently loaded three chemotherapeutic agents [bis-chloroethylnitrosourea, irinotecan, and cisplatin; BIC] into 50:50 poly[(d,l)-lactide-co-glycolide] (PLGA) nanofibres and an antiangiogenic agent (combretastatin) into 75:25 PLGA nanofibres [BIC and combretastatin (BICC)/PLGA]. The BICC/PLGA nanofibrous membranes were surgically implanted onto the brain surfaces of healthy rats for conducting pharmacodynamic studies and onto C6 glioma-bearing rats for estimating the therapeutic efficacy. The chemotherapeutic agents were rapidly released from the 50:50 PLGA nanofibres after implantation, followed by the release of combretastatin (approximately 2 weeks later) from the 75:25 PLGA nanofibres. All drug concentrations remained higher in brain tissues than in the blood for more than 8 weeks. The experimental results, including attenuated malignancy, retarded tumour growth, and prolonged survival in tumour-bearing rats, demonstrated the efficacy of the BICC/ PLGA nanofibrous membranes. Furthermore, the efficacy of BIC/PLGA and BICC/PLGA nanofibrous membranes was compared. The BICC/PLGA nanofibrous membranes more efficiently retarded the tumour growth and attenuated the malignancy of C6 glioma-bearing rats. Moreover, the addition of combretastatin did not significantly change the drug release behaviour of the BIC/PLGA nanofibrous membranes. The present advanced and novel interstitial chemotherapy and targeted treatment provide a potential strategy and regimen for treating GBM.
原文英語
頁(從 - 到)59902-59916
頁數15
期刊Oncotarget
7
發行號37
DOIs
出版狀態已發佈 - 2016

指紋

imidazole mustard
Glioma
Drug Therapy
Membranes
Nanofibers
Pharmaceutical Preparations
Therapeutics
irinotecan
Neoplasms
Glioblastoma
polylactic acid-polyglycolic acid copolymer
Angiogenesis Inhibitors
combretastatin
Brain
Growth
Brain Neoplasms
Cisplatin

ASJC Scopus subject areas

  • Oncology

引用此文

Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes. / Tseng, Yuan-Yun; Su, Chen Hsing; Yang, Shung-Tai; Huang, Yin Chen; Lee, Wei-Hwa; Wang, Yi Chuan; Liu, Shou Cheng; Liu, Shih Jung.

於: Oncotarget, 卷 7, 編號 37, 2016, p. 59902-59916.

研究成果: 雜誌貢獻文章

Tseng, Yuan-Yun ; Su, Chen Hsing ; Yang, Shung-Tai ; Huang, Yin Chen ; Lee, Wei-Hwa ; Wang, Yi Chuan ; Liu, Shou Cheng ; Liu, Shih Jung. / Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes. 於: Oncotarget. 2016 ; 卷 7, 編號 37. 頁 59902-59916.
@article{d804f64559b64c8c8c11dcf82755ed28,
title = "Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes",
abstract = "Glioblastoma multiforme (GBM), the most prevalent and malignant form of a primary brain tumour, is resistant to chemotherapy. In this study, we concurrently loaded three chemotherapeutic agents [bis-chloroethylnitrosourea, irinotecan, and cisplatin; BIC] into 50:50 poly[(d,l)-lactide-co-glycolide] (PLGA) nanofibres and an antiangiogenic agent (combretastatin) into 75:25 PLGA nanofibres [BIC and combretastatin (BICC)/PLGA]. The BICC/PLGA nanofibrous membranes were surgically implanted onto the brain surfaces of healthy rats for conducting pharmacodynamic studies and onto C6 glioma-bearing rats for estimating the therapeutic efficacy. The chemotherapeutic agents were rapidly released from the 50:50 PLGA nanofibres after implantation, followed by the release of combretastatin (approximately 2 weeks later) from the 75:25 PLGA nanofibres. All drug concentrations remained higher in brain tissues than in the blood for more than 8 weeks. The experimental results, including attenuated malignancy, retarded tumour growth, and prolonged survival in tumour-bearing rats, demonstrated the efficacy of the BICC/ PLGA nanofibrous membranes. Furthermore, the efficacy of BIC/PLGA and BICC/PLGA nanofibrous membranes was compared. The BICC/PLGA nanofibrous membranes more efficiently retarded the tumour growth and attenuated the malignancy of C6 glioma-bearing rats. Moreover, the addition of combretastatin did not significantly change the drug release behaviour of the BIC/PLGA nanofibrous membranes. The present advanced and novel interstitial chemotherapy and targeted treatment provide a potential strategy and regimen for treating GBM.",
keywords = "Antiangiogenesis, Chemotherapy, Glioblastoma multiforme (GBM), Nanofiber, Targeted therapy",
author = "Yuan-Yun Tseng and Su, {Chen Hsing} and Shung-Tai Yang and Huang, {Yin Chen} and Wei-Hwa Lee and Wang, {Yi Chuan} and Liu, {Shou Cheng} and Liu, {Shih Jung}",
year = "2016",
doi = "10.18632/oncotarget.10989",
language = "English",
volume = "7",
pages = "59902--59916",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "37",

}

TY - JOUR

T1 - Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes

AU - Tseng, Yuan-Yun

AU - Su, Chen Hsing

AU - Yang, Shung-Tai

AU - Huang, Yin Chen

AU - Lee, Wei-Hwa

AU - Wang, Yi Chuan

AU - Liu, Shou Cheng

AU - Liu, Shih Jung

PY - 2016

Y1 - 2016

N2 - Glioblastoma multiforme (GBM), the most prevalent and malignant form of a primary brain tumour, is resistant to chemotherapy. In this study, we concurrently loaded three chemotherapeutic agents [bis-chloroethylnitrosourea, irinotecan, and cisplatin; BIC] into 50:50 poly[(d,l)-lactide-co-glycolide] (PLGA) nanofibres and an antiangiogenic agent (combretastatin) into 75:25 PLGA nanofibres [BIC and combretastatin (BICC)/PLGA]. The BICC/PLGA nanofibrous membranes were surgically implanted onto the brain surfaces of healthy rats for conducting pharmacodynamic studies and onto C6 glioma-bearing rats for estimating the therapeutic efficacy. The chemotherapeutic agents were rapidly released from the 50:50 PLGA nanofibres after implantation, followed by the release of combretastatin (approximately 2 weeks later) from the 75:25 PLGA nanofibres. All drug concentrations remained higher in brain tissues than in the blood for more than 8 weeks. The experimental results, including attenuated malignancy, retarded tumour growth, and prolonged survival in tumour-bearing rats, demonstrated the efficacy of the BICC/ PLGA nanofibrous membranes. Furthermore, the efficacy of BIC/PLGA and BICC/PLGA nanofibrous membranes was compared. The BICC/PLGA nanofibrous membranes more efficiently retarded the tumour growth and attenuated the malignancy of C6 glioma-bearing rats. Moreover, the addition of combretastatin did not significantly change the drug release behaviour of the BIC/PLGA nanofibrous membranes. The present advanced and novel interstitial chemotherapy and targeted treatment provide a potential strategy and regimen for treating GBM.

AB - Glioblastoma multiforme (GBM), the most prevalent and malignant form of a primary brain tumour, is resistant to chemotherapy. In this study, we concurrently loaded three chemotherapeutic agents [bis-chloroethylnitrosourea, irinotecan, and cisplatin; BIC] into 50:50 poly[(d,l)-lactide-co-glycolide] (PLGA) nanofibres and an antiangiogenic agent (combretastatin) into 75:25 PLGA nanofibres [BIC and combretastatin (BICC)/PLGA]. The BICC/PLGA nanofibrous membranes were surgically implanted onto the brain surfaces of healthy rats for conducting pharmacodynamic studies and onto C6 glioma-bearing rats for estimating the therapeutic efficacy. The chemotherapeutic agents were rapidly released from the 50:50 PLGA nanofibres after implantation, followed by the release of combretastatin (approximately 2 weeks later) from the 75:25 PLGA nanofibres. All drug concentrations remained higher in brain tissues than in the blood for more than 8 weeks. The experimental results, including attenuated malignancy, retarded tumour growth, and prolonged survival in tumour-bearing rats, demonstrated the efficacy of the BICC/ PLGA nanofibrous membranes. Furthermore, the efficacy of BIC/PLGA and BICC/PLGA nanofibrous membranes was compared. The BICC/PLGA nanofibrous membranes more efficiently retarded the tumour growth and attenuated the malignancy of C6 glioma-bearing rats. Moreover, the addition of combretastatin did not significantly change the drug release behaviour of the BIC/PLGA nanofibrous membranes. The present advanced and novel interstitial chemotherapy and targeted treatment provide a potential strategy and regimen for treating GBM.

KW - Antiangiogenesis

KW - Chemotherapy

KW - Glioblastoma multiforme (GBM)

KW - Nanofiber

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84991383794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991383794&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10989

DO - 10.18632/oncotarget.10989

M3 - Article

VL - 7

SP - 59902

EP - 59916

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 37

ER -